Asarfi Hospital Reports Strong Q2 Growth, Secures ₹6.68 Crore Loan for Expansion
Asarfi Hospital Limited reported robust financial results for Q2 and H1 FY2026. Revenue grew 45% YoY to ₹44.85 crore in Q2, and 50% YoY to ₹80.51 crore in H1. EBITDA and PAT margins remained strong. Operational metrics improved, with increased ARPOB and occupancy rates in both super-specialty and cancer units. The company secured funding for expansion, including a ₹4.68 crore term loan for a new Cath Lab and a ₹2 crore bank guarantee limit. A partnership with Gleneagles Chennai aims to establish Jharkhand's first Multi-Organ Transplant Unit. Asarfi Hospital's Vision 2027 targets 500 beds, ₹200 crore in revenues, and improved margins.
*this image is generated using AI for illustrative purposes only.
Asarfi Hospital Limited , a leading healthcare provider in Eastern India, has reported robust financial results for the second quarter and half-year ended September 30, 2025, alongside securing significant funding for expansion.
Financial Highlights
The company's standalone financial results show impressive growth:
| Metric | Q2 FY2026 | YoY Growth | H1 FY2026 | YoY Growth |
|---|---|---|---|---|
| Revenue | ₹44.85 crore | 45% | ₹80.51 crore | 50% |
| EBITDA | ₹8.91 crore | 31% | ₹15.94 crore | 37% |
| EBITDA Margin | 20.00% | - | 20.00% | - |
| PAT | ₹4.30 crore | 48% | ₹7.50 crore | 69% |
| PAT Margin | 10.00% | - | 9.00% | - |
The consolidated results mirror this strong performance, with revenue reaching ₹80.57 crore for H1 FY2026, marking a 50% year-on-year increase.
Operational Performance
Asarfi Hospital has shown significant improvement in key operational metrics:
Super-Specialty Hospital Unit
- ARPOB (Average Revenue Per Occupied Bed) increased to ₹19,839 in H1 FY2026 from ₹16,925 in H1 FY2025
- Bed occupancy rate improved to 64% from 59% year-on-year
Cancer Hospital Unit
- ARPOB saw a substantial rise to ₹41,401 in H1 FY2026 from ₹16,602 in H1 FY2025
- Occupancy rate increased to 44% from 26% year-on-year
Expansion and Funding
During the quarter, Asarfi Hospital secured important funding for its growth initiatives:
- A term loan of ₹4.68 crore from State Bank of India for purchasing and installing a new Cath Lab at their Dhanbad facility
- A ₹2.00 crore fund-based Bank Guarantee limit for corporate and PSU empanelments
These financial arrangements are expected to enhance the hospital's capabilities and market position.
Strategic Developments
The company has entered into a partnership with Gleneagles Chennai to establish Jharkhand's first-ever Multi-Organ Transplant Unit. This collaboration aims to provide world-class transplant services for heart, lungs, kidney, liver, and bone marrow under one roof, potentially transforming Jharkhand from a "Medical Desert" into a "Medical Destination."
Future Outlook
Asarfi Hospital's Vision 2027 includes ambitious targets:
- Expanding to 500 beds
- Achieving ₹200 crore in revenues
- Maintaining EBITDA margins of 25-27%
- Targeting PAT margins of 13-15%
The company plans to increase bed capacity in its super-specialty hospital from 265 to 350 and in the cancer hospital from 65 to 150 within the next two years.
With its strong financial performance, strategic expansions, and partnerships, Asarfi Hospital Limited appears well-positioned for continued growth in the healthcare sector of Eastern India.
Historical Stock Returns for Asarfi Hospital
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.25% | +14.59% | +38.20% | +72.30% | +138.46% | +94.24% |
18
